In a clinical trial for a COVID-19 vaccine developed by Pfizer, a US pharmaceutical company, some participants had mild to moderate side effects, Reuters reported.
Pfizer, who introduced the Corona 19 vaccine together with Bioentech, Germany, said that the report was reported as a result of conducting a phase 3 clinical trial on 29,000 out of 44,000 volunteers.
More than 12,000 of these received the second dose of the vaccine.
In a conference call to investors, Pfizer explained that the vaccine's safety and tolerance are continually being scrutinized through clinical trials.
However, he added that although the company's independent data review committee may recommend stopping the vaccine study at any time, it has not yet taken such action.
Pfizer's reports of adverse reactions to clinical trials were released shortly after AstraZeneca, UK, suspended the vaccine trial on the 6th due to serious side effects.
(Photo = Getty Image Korea)